Increased matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase activity and expression in heterotopically transplanted murine tracheas

Journal of Heart and Lung Transplantation

Volumn 23, Issue 2, 2004, Pages 218-227

  Inaki, Noriyuki ^a   Tsunezuka, Yoshio ^a   Kawakami, Kazuyuki ^a   Sato, Hiroshi ^a   Takino, Takahisa ^a   Oda, Makoto ^a   Watanabe, Go ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHIOLITIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; FIBROSIS; GENE EXPRESSION; HETEROTOPIC TRANSPLANTATION; HISTOLOGY; ISOGRAFT; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TRACHEA MUCOSA; TRACHEA STENOSIS; ZYMOGRAPHY;

EID: 0842264745     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(03)00112-8     Document Type: Article

References (56)

1. Reichenspurner H., Girgis R.E., Robbins R.C., Conte J.V., Nair R.V., Valentine V., Berry G.J., Morris R.E., Theodore J., Reitz B.A. Obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg. 60:(6):1995;1845-1853.
2. Hasegawa S., Ockner D.M., Ritter J.H., Patterson G.A., Trulock E.P., Cooper J.D., Wick M.R. Expression of class II major histocompatibility complex antigens (HLA-DR) and lymphocyte subset immunotyping in chronic pulmonary transplant rejection. Arch Pathol Lab Med. 119:(5):1995;432-439.
3. Reznik S.I., Jaramillo A., SivaSai K.S., Womer K.L., Sayegh M.H., Trulock E.P., Patterson G.A., Mohanakumar T. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant. 1:(3):2001;228-235.
4. SivaSai K.S., Smith M.A., Poindexter N.J., Sundaresan S.R., Trulock E.P., Lynch J.P., Cooper J.D., Patterson G.A., Mohanakumar T. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation. 67:(8):1999;1094-1098.
5. Whitford H., Walters E.H., Levvey B., Kotsimbos T., Orsida B., Ward C., Pais M., Reid S., Williams T., Snell G. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation a double-blind, placebo-controlled trial . Transplantation. 73:(11):2002;1793-1799.
6. Paradis I. Bronchiolitis obliterans pathogenesis, prevention, and management . Am J Med Sci. 315:(3):1998;161-178.
7. Adams B.F., Berry G.J., Huang X., Shorthouse R., Brazelton T., Morris R.E. Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts. Transplantation. 69:(11):2000;2260-2266.
8. Billingham M.E. Pathology of graft vascular disease after heart and heart-lung transplantation and its relationship to obliterative bronchiolitis. Transplant Proc. 27:1995;2013-2016.
9. Paradis I.L., Yousem S.A., Griffith B.P. Airway obstruction and bronchitis obliterans after lung transplantation. Clin Chest Med. 14:1993;751-763.
10. Cooper J.D., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant. 12:1993;713-716.
11. Griffith B.P., Paradis I.L., Zeevi A. Immunologically mediated disease of the airways after lung transplantation. Ann Surg. 208:1988;371-378.
12. Tsunezuka Y., Kinoh H., Takino T., et al. Expression of membrane-type matrix metalloproteinase-1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res. 56:1996;5678-5683.
13. Kinoh H., Sato H., Tsunezuka Y., et al. MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci. 109:1996;953-959.
14. Sato H., Takino T., Okada Y., et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature. 370:1994;61-65.
15. Nomura H., Sato H., Seiki M., Mai M., Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55:1995;3263-3266.
16. Okada A., Bellocq J., Rouyer N., et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA. 92:1995;2730-2734.
17. Maekawa R., Maki H., Yoshida H., et al. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 59:(6):1999;1231-1235.
18. Cataldo D., Munaut C., Noel A., et al. MMP-2-and MMP-9- linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allerg Immunol. 123:(3):2000;259-267.
19. Ohnishi K., Takagi M., Kurokawa Y., Satomi S., Konttinen Y.T. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest. 78:(9):1998;1077-1087.
20. Fukuda Y., Ishizaki M., Kudoh S., Kitaichi M., Yamanaka N. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinases-2 in intestinal lung disease. Lab Invest. 78:(6):1998;687-689.
21. Kojima S., Itoh Y., Matsumoto S., Masuho Y., Seiki M. Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP. FEBS Lett. 480:(2):2000;142-146.
22. Hertz M.I., Jessurun J., King M.B., Savik S.K., Murray J. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol. 142:1993;1945-1951.
23. Huang X., Reuchenspurner H., Shorthouse R., Cao W., Berry G., Morris R. Heterotopic tracheal allograft transplantation a new model to study the molecular events causing obliterative airway disease in rats . J Heart Lung Transplant. 14:(suppl):1995;S49.
24. Kelly K.E., Hertz M.I., Mueller D.L. T-cell and major histocompatibility complex requirements for obliterative airway disease in heterotopically transplanted murine tracheas. Transplantation. 66:(6):1998;764-771.
25. Hibbs M.S., Hasty K.A., Seyer J.M., Kang A.H., Marinardi C.L.A. Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem. 260:1985;2493-2500.
26. Peterson G.L. A simplification of the protein assay method of Lowry et al., which is more generally applicable. Anal Biochem. 83:1977;346-356.
27. Brown P.D., Kleiner D.E., Unsworth E.J., Stetler-Stevenson W.G. Cellular activation of the 72kDa type IV procollagenase/TIMP-2 complex. Kidney Int. 43:1993;163-170.
28. Overall C.M., Wrana J.L., Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloproteinase inhibitor expression in human fibroblasts by transforming growth factor-β J Biol Chem. 264:1989;1860-1869.
29. Gibson U.E., Heid C.A., Williams P.M. A novel method for real time quantitative RT-PCR. Genome Res. 6:(10):1996;995-1001.
30. Heid C.A., Stevens J., Livak K.J., Williams P.M. Real time quantitative PCR. Genome Res. 6:1996;986-994.
31. Chomezynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
32. Bender C.M., Pao M.M., Jones P.A. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58:1998;95-101.
33. Livak K.J., Flood S.J., Marmaro J., Giusti W., Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Meth Appl. 4:1995;357-362.
34. Yasufuku K., Heidler K.M., Woods K.A., et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation. 73:2002;500-505.
35. Tikkanen J.M., Lemstrom K.B., Koskinen P.K. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts suppression of helper T cell type 1-dominated immune response . Am J Respir Crit Care. 165:(5):2002;724-729.
36. Liu M., Suga M., Maclean A.A., St George J.A., Souza D.W., Keshavjee S. Soluble transforming growth factor-beta type III receptor gene transfection inhibits fibrous airway obliteration in a rat model of bronchiolitis obliterans. Am J Respir Crit Care Med. 165:(3):2002;419-423.
37. Roth-Eichhorn S., Schade I., Kasper M., et al. Anti-proliferative properties of the phosphodiesterase-4 inhibitor rolipram can supplement immunosuppressive effects of cyclosporine for treatment of obliterative bronchiolitis in heterotopic rat allografts. J Heart Lung Transplant. 20:(11):2001;1188-1198.
38. Tikkanen J.M., Kallio E.A., Bruggeman C.A., Koskinen P.K., Lemstrom K.B. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med. 164:(4):2001;672-679.
39. Philip T.C. Lung transplant pathology. William M.T., Andrew M.C. Pathology of the lung. 1995;827-849 Thieme, New York.
40. Nomura H., Sato H., Seiki M., Mai M., Okada Y. Expression of membrane type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55:1995;3263-3266.
41. Tokuraku M., Sato H., Murakami S., Okada Y., Watanabe Y., Seiki M. Activation of precursor of gelatinase A/72kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer. 64:1995;355-359.
42. Ueno H., Nakamura H., Inoue M., et al. Expression and tissue localization of membrane types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 57:1997;2055-2060.
43. Winkler M.K., Fowlkes J.L. Metalloproteinase and growth factor interactions do they play a role in pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 283:(1):2002;L1-L11.
44. Okada Y., Gonoji Y., Nakata K., et al. Matrix metalloproteinase 9(92-kd gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem. 267:1992;21712-21719.
45. Okada Y., Morodomi T., Enghild J.J., et al. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem. 194:1990;721-730.
46. Vignola A.M., Riccobono L., Mirabella A., et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med. 158:(6):1998;1945-1950.
47. Beeh K.M., Beier J., Kornmann O., Micke P., Buhl R. Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients relation to tumor necrosis factor-alpha and interleukin-10 . J Heart Lung Transplant. 20:(11):2001;1144-1151.
48. Yano M., Omoto Y., Yamakawa Y., Nakashima Y., Kiriyama M., Saito Y., Fujii Y. Increased matrix metalloproteinase 9 activity and mRNA expression in lung ischemia-reperfusion injury. J Heart Lung Transplant. 20:(6):2001;679-686.
49. Huhtala P., Tuuttila A., Chow L.T., Lohi J., Keski-Oja J., Tryggvason K. Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem. 266:(25):1991;16485-16490.
50. Trello C.A., Williams D.A., Keller C.A., Crim C., Webster R.O., Ohar J.A. Increased gelatinolytic activity in bronchoalveolar lavage fluid in stable lung transplant recipients. Am J Respir Crit Care Med. 156:(6):1997;1978-1986.
51. Hewitson T.D., Kelynack K.J., Tait M.G., et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol. 14:(6):2001;453-460.
52. Adhikary L.P., Yamamoto T., Isome M., et al. Expression profile of extracellular matrix and its regulatory proteins during the process of interstitial fibrosis after anti-glomerular basement membrane antibody-induced glomerular sclerosis in Sprague-Dawley rats. Pathol Int. 49:(8):1999;716-725.
53. Aeret N., Lehti K., Musso O., Clement B. MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology. 30:(2):1999;462-468.
54. Suga M., Iyonaga K., Okamoto T., et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 162:(5):2000;1949-1956.
55. Esparza J., Vilardell C., Calvo J., et al. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood. 15:94:(8):1999;2754- 2766.
56. Foda H.D., Rollo E.E., Brown P., et al. Attenuation of oxidant-induced lung injury by the synthetic matrix metalloproteinase inhibitor BB-3103. Ann NY Acad Sci. 878:1999;650-653.